{"name":"Anterogen Co., Ltd.","slug":"anterogen-co-ltd","ticker":"","exchange":"","domain":"anterogen.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"immunology","drugs":[{"name":"ALLO-ASC-TI","genericName":"ALLO-ASC-TI","slug":"allo-asc-ti","indication":"Other","status":"phase_1"},{"name":"ALLO-ASC-CD","genericName":"ALLO-ASC-CD","slug":"allo-asc-cd","indication":"Other","status":"phase_2"},{"name":"ALLO-ASC-SHEET","genericName":"ALLO-ASC-SHEET","slug":"allo-asc-sheet","indication":"Other","status":"phase_2"},{"name":"ANT-301","genericName":"ANT-301","slug":"ant-301","indication":"Other","status":"phase_1"},{"name":"Adipocell","genericName":"Adipocell","slug":"adipocell","indication":"Other","status":"phase_2"},{"name":"Fibringlue","genericName":"Fibringlue","slug":"fibringlue","indication":"Other","status":"phase_3"},{"name":"Repaircell","genericName":"Repaircell","slug":"repaircell","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ALLO-ASC-DFU","genericName":"ALLO-ASC-DFU","slug":"allo-asc-dfu","indication":"Diabetic foot ulcers (DFU)","status":"phase_3"},{"name":"ADIPOPLUS","genericName":"ADIPOPLUS","slug":"adipoplus","indication":"Type 2 diabetes","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ASC","genericName":"ASC","slug":"asc","indication":"Osteoarthritis (knee)","status":"marketed"}]}],"pipeline":[{"name":"ALLO-ASC-DFU","genericName":"ALLO-ASC-DFU","slug":"allo-asc-dfu","phase":"phase_3","mechanism":"ALLO-ASC-DFU is an allogeneic adipose-derived mesenchymal stem cell therapy that promotes wound healing and tissue regeneration in diabetic foot ulcers.","indications":["Diabetic foot ulcers (DFU)"],"catalyst":""},{"name":"ALLO-ASC-TI","genericName":"ALLO-ASC-TI","slug":"allo-asc-ti","phase":"phase_1","mechanism":"Allogeneic adipose-derived mesenchymal stem cells with potential immunomodulatory and tissue regenerative properties.","indications":[],"catalyst":""},{"name":"ADIPOPLUS","genericName":"ADIPOPLUS","slug":"adipoplus","phase":"phase_2","mechanism":"ADIPOPLUS is a small molecule that targets the SIRT1 pathway to enhance adipocyte function and glucose metabolism.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"ALLO-ASC-CD","genericName":"ALLO-ASC-CD","slug":"allo-asc-cd","phase":"phase_2","mechanism":"Allogeneic adipose-derived stem cells that may modulate immune responses and promote tissue repair through paracrine signaling.","indications":[],"catalyst":""},{"name":"ALLO-ASC-SHEET","genericName":"ALLO-ASC-SHEET","slug":"allo-asc-sheet","phase":"phase_2","mechanism":"Allogeneic adipose-derived stem cell sheet that may provide regenerative effects through paracrine signaling and tissue repair mechanisms.","indications":[],"catalyst":""},{"name":"ANT-301","genericName":"ANT-301","slug":"ant-301","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ASC","genericName":"ASC","slug":"asc","phase":"marketed","mechanism":"ASC is an autologous stem cell therapy that promotes tissue regeneration and repair through the patient's own stem cells.","indications":["Osteoarthritis (knee)","Cartilage defects"],"catalyst":""},{"name":"Adipocell","genericName":"Adipocell","slug":"adipocell","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fibringlue","genericName":"Fibringlue","slug":"fibringlue","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Repaircell","genericName":"Repaircell","slug":"repaircell","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxPaUpjZWVBaHRGWXRIZ3Zibk1KT0pHaTNlUFd2aVhvaHZmSGFBcVBPeDVIdGQ1M2oyRVNWQ21wSVNqOXZseVNTX1lwU0lZcE9tbFVKVHlvVTUybzFiOFdHc1lialNhYXVmTHNzTHFRZGxRS1N3M2UzdUNDeXZvR3ZwTGJkdk1iaXJSWkVzT3NVZkUzWmJBM00tZEtuclVNMk52NUJqN1RGbjhCMjh1VmRRUmMtVElCZGtFZVI0UHd2bW81NmZjR3ZXZkZJY0JhWUtQZ0ZsbnpIbW11Q3BtQkhJeVhlQ1gwNFFlT2pzTFdZbVhJV3hkQTFVUktYQWdmSUJTSzdvbUFYT1Y1aW5UUHdEUW1jNy0wRU9Zb1R2MzJYNHZaeDhQODlYQkRDUG9kcExoa0dzWUxESktqY0hEMkZFQTVHQzJ2aGdKdURJUzNhMzA?oc=5","date":"2025-10-09","type":"regulatory","source":"Business Wire","summary":"Mesenchymal Stem Cells/Medicinal Signaling Cells Advances & Applications Report 2025: 1,670+ Trials, 12 Approvals Worldwide, and Path to 50 Approvals by 2040 - ResearchAndMarkets.com - Business Wire","headline":"Mesenchymal Stem Cells/Medicinal Signaling Cells Advances & Applications Report 2025: 1,670+ Trials, 12 Approvals Worldw","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxOOEVpcy1BTVpvNDEtTW9vNHBCSmZOYXZTOUlJaWE4ck5oTlRlTnBLZDRVNko4WmU1SGVBUW9ZRWxOdWxwRmpBWThIVE1kNm1XLWZnbTlZYkpOMnFMZXR4a2h0WTJVcTJHVmJWVDhEMDZQOGpDRFZOY0lvY1VLb2JRanZ4U1d5MFVqRGs3SkREczRIa01XYnlXNF8tbWVXT3dKTXRJTkhmRmpQNS11SUliV0Nfak5WNzlHbmZGbkVycURrZ0RQb2QzVmljRkxJV2RKN0xrQ1ZkVW1HVlo5Yi1US0xWeGJBLUVTRGlVeUxfem9wbVNRN01jNjNpUVB2VXhF?oc=5","date":"2025-08-07","type":"pipeline","source":"BioSpace","summary":"Stem Cell Therapy Market Size to Hit USD 78.39 Billion by 2032, Growing at a CAGR of 22.8% from 2025 to 2032 | Coherent Market Insights - BioSpace","headline":"Stem Cell Therapy Market Size to Hit USD 78.39 Billion by 2032, Growing at a CAGR of 22.8% from 2025 to 2032 | Coherent ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPTGFlNmx0T2ZSSXpIclNPMjdnLVUxX3JkUHB1REtfbzdhcktLbkI5X3pVT0NWYXFKSGNFT1g5alRCNTlXOUs4R040V28tTXZrNXNrVzROYlFTTUtsMDQweldLYnY3cEZ2eU16ZjdkWnJmcENhaURsVTZ0MlJoYWpWd3lMdlMtR0thY3BpZEVaV3JWdFpWSm81ZjhUdnZSaEhyTDFDdjdzNF9pMC1IcmlZQjcwcWJxRTlsY2M0NHE1TUlxVDNPMDZ3RklpcjRCMHNRVnF5VzQzR3BUVWNyZF9JWUhyc210TzR6YzZjakp6cE9vRzIxOVRNWlVR?oc=5","date":"2025-05-22","type":"regulatory","source":"PR Newswire","summary":"ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market | DelveInsight - PR Newswire","headline":"ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market | DelveInsight","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPWFhzUTI4RW5pRmx6dzFIYUZ0V3AtZGlCUnJyZkplYzQ3SVdWRnNXXzJxdzJqellKUGNFRVkzdS1xOTVnWmc5U3NUMXdfd1daYmx1NWVjZEVQcVJ4UXlTNTdHSkpXZTllbXNhZTEwMTJUYlg0LXF0bzZoNXNDa29PV21fWnJOX1owOXZtcURYYURsWjhSQm1GbXc3T0FKVjlHUTNBUXo2Q3FyUFFaTC1aUXhpZmhZUQ?oc=5","date":"2025-02-14","type":"pipeline","source":"BioSpace","summary":"Cell Therapy Market Size Uplifts USD 44.39 Bn at 22.69% Healthy CAGR by 2034 - BioSpace","headline":"Cell Therapy Market Size Uplifts USD 44.39 Bn at 22.69% Healthy CAGR by 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9rWXBIOTFyYmVxbThpQmRoTEpydEZVVFFuLWlzNmktaWluX3NqdzVvdDcxTmZybUlXYktWcGZ4dnNRSWpwTXM3anFxVi05TkhrcmZXQ0k3Z1hEMTBuRTdMbEhDaTRiZlVoMlV4SXd30gFyQVVfeXFMTmxWNGZCdjBvcVZ0cFFjNFN1T3BvbzZ5QjdZcmFBREVvTnNibHhvMDViMzdLT0NMVm5mUGxWeG9iYVFvWno1QllGS3JMaDhydjRVUlQwWENwTzF2dVlsMU5lTjFIUlNDRDlvd05wZHR6WmFR?oc=5","date":"2025-02-03","type":"trial","source":"koreabiomed.com","summary":"Anterogen’s stem cell therapy fails US phase 2 trial for diabetic foot ulcers, shifting focus to severe cases - koreabiomed.com","headline":"Anterogen’s stem cell therapy fails US phase 2 trial for diabetic foot ulcers, shifting focus to severe cases","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9fcGx4OHZNZk94VDZrZTdINmtRVTJXOVdmS0FEQlAtOWtLcFJzRE4zNHhWcmI2dW9CTDl2LXAya1NUYmVxQUxlS1pXd0Z0TEdNbkhYOWpGVklrWHE0cEpyNmcyUDRsTXJqM3NPMDN0VG5Fd9IBd0FVX3lxTFBMdURJVWJ2NG8zMUNyQl94Vm8wN1IxaVVYa0YwVkhRRlZHUldFY0ZyeDg3QnpLblcya0RPaVFkMktPNEEzRGpVOHJ0Z0QxQUI3SVF4QTJoWEF5MHZVS0NxYnA0VHZjUV85bFA4d083eFJHQ3RwNnlr?oc=5","date":"2025-01-13","type":"regulatory","source":"BioInformant","summary":"China’s NMPA Approves Country’s First MSC-Based Cell Therapy, Ruibosheng - BioInformant","headline":"China’s NMPA Approves Country’s First MSC-Based Cell Therapy, Ruibosheng","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQNl9DaTB2Q01KSXA1NmZjRm9pcGhtNjR3UnlwVTZCRXFxVngyWlRqRXhfLWNFZDJLNEpFSy16QVZzZ3QyVk5ISkp1ZGJ5MUxTa1M2V2ZfUVpEYkV3QUZIdnQzZWRpVDFsLVptRDZZb3JPa3FoQTlGckJ3aDAwcnlxR3RCR0RDaURvR0hGRlprdU0wOUlJ?oc=5","date":"2023-12-12","type":"pipeline","source":"BioSpace","summary":"CAR T-Cell Therapy Market Size, Share, Growth, Trends, Report By 2032 - BioSpace","headline":"CAR T-Cell Therapy Market Size, Share, Growth, Trends, Report By 2032","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5vS2dEWDRKSGV0WGFMQ2djZG9ka3lnd2M1RENtUkEwRmVINENLSHI5NjEtS3h6dVp4SnBldDI5MWpidWEtNEZQSm1FbXJiWC1jcUlwVUt2VEpnQ25tX3M1bDM1WV83cFnSAWxBVV95cUxOSFNFejlEdTJ5S3hqdENfTTZIRFV6SVFVWkN6U3hLd2JETlBHcTUyY3RhZ3JheWh4WmVSTkM1OE82V3g3RVVUaW54amU0WFhudk1ZaFRmR3VHY2dLVG9KeTdZdE5IWHdyb0dSbUY?oc=5","date":"2023-11-28","type":"regulatory","source":"BioInformant","summary":"Pricing Of Approved Cell Therapy Products - BioInformant","headline":"Pricing Of Approved Cell Therapy Products","sentiment":"positive"}],"patents":[],"drugCount":10,"phaseCounts":{"phase_3":2,"phase_1":3,"phase_2":4,"marketed":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}